These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 38945936)

  • 1. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-Amyloid Antibody Therapy for Alzheimer's Disease].
    Shinohara M; Ono K
    Brain Nerve; 2024 Oct; 76(10):1119-1125. PubMed ID: 39370836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model.
    Song Y; Dai CL; Shinohara M; Chyn Tung Y; Zhou S; Huang WC; Seffouh A; Luo Y; Willadsen M; Jiao Y; Morishima M; Saito Y; Koh SH; Ortega J; Gong CX; Lovell JF
    Brain Behav Immun; 2024 Nov; 122():185-201. PubMed ID: 39142420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.
    Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S
    Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-Directed Antibodies: Past, Present, and Future.
    Noorda K; Noorda K; Sabbagh MN; Bertelson J; Singer J; Decourt B
    J Alzheimers Dis; 2024; 101(s1):S3-S22. PubMed ID: 39422953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease.
    Zhang W; Smith N; Zhou Y; McGee CM; Bartoli M; Fu S; Chen J; Domena JB; Joji A; Burr H; Lv G; Cilingir EK; Bedendo S; Claure ML; Tagliaferro A; Eliezer D; Veliz EA; Zhang F; Wang C; Leblanc RM
    Acta Biomater; 2024 Jul; 183():341-355. PubMed ID: 38849023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
    Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
    Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.